Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990

Market snapshot: Zydus Lifesciences (ZYDUSLIFE) has officially entered the high-growth med-tech segment in India with the launch of Pepair™, an affordable, drug-free Oscillating Positive Expiratory Pressure (OPEP) device. This move signifies a strategic pivot from traditional pharmaceutical formulations toward integrated patient care solutions. Following a stellar Q3 FY26 performance, where the company reported a 30% YoY revenue jump, this launch reinforces Zydus’s dominance in the domestic chronic therapy market.

Summary: Zydus Lifesciences launches Pepair™, an OPEP device for COPD and Asthma, priced at an industry-disrupting ₹990, targeting a massive respiratory patient base in India.

Key Takeaways

• Affordability Play: Priced at ₹990, Pepair™ is significantly cheaper than existing OPEP solutions, lowering the barrier for chronic airway clearance.
• Strategic Diversification: The launch represents Zydus’s deepening footprint in Medical Technology (MedTech) alongside its core drug business.
• Vast Addressable Market: Targeting over 90 lakh chronic respiratory patients in India (COPD, Asthma, Bronchiectasis) who require drug-free mucus clearance.

SAHI Perspective

Zydus is leveraging its established distribution network in the respiratory therapy segment to cross-sell med-tech hardware. By pricing the device under ₹1,000, they are not just selling a product but building a lifelong patient-brand ecosystem. This aligns with their broader 'Patient Centricity' strategy, moving beyond pills to holistic health management. From a valuation standpoint, the med-tech division (which contributed significantly in Q3 via acquisitions like Amplitude Surgical) offers higher margins and lower regulatory volatility compared to traditional generic exports.

Closing Insight

With Pepair™, Zydus isn't just launching a device; it is establishing a new standard for affordable respiratory diagnostics and care in the Global South.

High Performance Trading with SAHI.

Synthetically modified: AI-generated content by Sahi Live News Engine.